...
首页> 外文期刊>Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology >First clinical trial of specific I-KACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation
【24h】

First clinical trial of specific I-KACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation

机译:特定的I-KACh阻滞剂的首次临床试验表明,阵发性心房颤动患者的房颤负担没有减少:阵发性心房颤动患者的BMS 914392起搏器评估

获取原文
获取原文并翻译 | 示例
           

摘要

Aims To assess the efficacy of BMS 914392 on atrial fibrillation (AF) burden reduction in 20 patients with pacemakers and paroxysmal atrial fibrillation (PAF). BMS 914392 is a potent, selective, oral inhibitor of the I-KACh current and has been shown to suppress AF, whilst having no effect on the ventricular refractory period. This is the first efficacy study of BMS 914392 in patients with PAF.
机译:目的评估BMS 914392在20例起搏器和阵发性房颤(PAF)患者中减少房颤(AF)负担的疗效。 BMS 914392是一种有效的,选择性的I-KACh电流的口服抑制剂,已显示出抑制AF的作用,而对心室不应期没有影响。这是BMS 914392对PAF患者的首次疗效研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号